Literature DB >> 26921334

Extracellular Adenosine Production by ecto-5'-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis.

Florian Wirsdörfer1, Simone de Leve1, Federica Cappuccini1, Therese Eldh2, Alina V Meyer1, Eva Gau1, Linda F Thompson3, Ning-Yuan Chen4, Harry Karmouty-Quintana4, Ute Fischer5, Michael Kasper6, Diana Klein1, Jerry W Ritchey7, Michael R Blackburn4, Astrid M Westendorf8, Martin Stuschke9, Verena Jendrossek10.   

Abstract

Radiation-induced pulmonary fibrosis is a severe side effect of thoracic irradiation, but its pathogenesis remains poorly understood and no effective treatment is available. In this study, we investigated the role of the extracellular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after thoracic irradiation. Exposure of wild-type C57BL/6 mice to a single dose (15 Gray) of whole thorax irradiation triggered a progressive increase in CD73 activity in the lung between 3 and 30 weeks postirradiation. In parallel, adenosine levels in bronchoalveolar lavage fluid (BALF) were increased by approximately 3-fold. Histologic evidence of lung fibrosis was observed by 25 weeks after irradiation. Conversely, CD73-deficient mice failed to accumulate adenosine in BALF and exhibited significantly less radiation-induced lung fibrosis (P < 0.010). Furthermore, treatment of wild-type mice with pegylated adenosine deaminase or CD73 antibodies also significantly reduced radiation-induced lung fibrosis. Taken together, our findings demonstrate that CD73 potentiates radiation-induced lung fibrosis, suggesting that existing pharmacologic strategies for modulating adenosine may be effective in limiting lung toxicities associated with the treatment of thoracic malignancies. Cancer Res; 76(10); 3045-56. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26921334      PMCID: PMC4960984          DOI: 10.1158/0008-5472.CAN-15-2310

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Radiation pulmonary toxicity: from mechanisms to management.

Authors:  Paul R Graves; Farzan Siddiqui; Mitchell S Anscher; Benjamin Movsas
Journal:  Semin Radiat Oncol       Date:  2010-07       Impact factor: 5.934

Review 2.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.

Authors:  Søren M Bentzen
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

3.  Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury.

Authors:  Jonathan B Volmer; Linda F Thompson; Michael R Blackburn
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

4.  A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury.

Authors:  Chun-Xiao Sun; Hays W Young; Jose G Molina; Jonathan B Volmer; Jurgen Schnermann; Michael R Blackburn
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

5.  Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.

Authors:  Chris R Kelsey; Mitchell E Horwitz; Junzo P Chino; Oana Craciunescu; Beverly Steffey; Rodney J Folz; Nelson J Chao; David A Rizzieri; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

6.  Ecto-5'-nucleotidase activity in T and B lymphocytes from normal subjects and patients with congenital X-linked agammaglobulinemia.

Authors:  L F Thompson; G R Boss; H L Spiegelberg; I V Jansen; R D O'Connor; T A Waldmann; R N Hamburger; J E Seegmiller
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  Human lymphocytes: 5'-nucleotidase-positive and -negative subpopulations.

Authors:  R Silber; M Conklyn; G Grusky; D Zucker-Franklin
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.

Authors:  M Wakamiya; M R Blackburn; R Jurecic; M J McArthur; R S Geske; J Cartwright; K Mitani; S Vaishnav; J W Belmont; R E Kellems
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

Review 9.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

10.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

View more
  29 in total

Review 1.  Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).

Authors:  Marquet Minor; Karel P Alcedo; Rachel A Battaglia; Natasha T Snider
Journal:  Am J Physiol Cell Physiol       Date:  2019-08-28       Impact factor: 4.249

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.

Authors:  Fabrícia Dietrich; Fabrício Figueiró; Eduardo Cremonese Filippi-Chiela; Angélica Regina Cappellari; Liliana Rockenbach; Alain Tremblay; Patrícia Boni de Paula; Rafael Roesler; Aroldo Braga Filho; Jean Sévigny; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

4.  Loss of CD73 prevents accumulation of alternatively activated macrophages and the formation of prefibrotic macrophage clusters in irradiated lungs.

Authors:  Simone de Leve; Florian Wirsdörfer; Federica Cappuccini; Alexandra Schütze; Alina V Meyer; Katharina Röck; Linda F Thompson; Jens W Fischer; Martin Stuschke; Verena Jendrossek
Journal:  FASEB J       Date:  2017-03-21       Impact factor: 5.191

Review 5.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Authors:  Borja Ruiz-Fernández de Córdoba; Haritz Moreno; Fernando Lecanda; Rafael Martínez-Monge; Karmele Valencia; Naiara Perurena; Pablo Ruedas; Thomas Walle; Alberto Pezonaga-Torres; Juan Hinojosa; Elisabet Guruceaga; Antonio Pineda-Lucena; Marta Abengózar-Muela; Denis Cochonneau; Carolina Zandueta; Susana Martínez-Canarias; Álvaro Teijeira; Daniel Ajona; Sergio Ortiz-Espinosa; Xabier Morales; Carlos Ortiz de Solórzano; Marta Santisteban; Luis I Ramos-García; Laura Guembe; Vratislav Strnad; Dominique Heymann; Sandra Hervás-Stubbs; Rubén Pío; María E Rodríguez-Ruiz; Carlos E de Andrea; Silvestre Vicent; Ignacio Melero
Journal:  Cancer Discov       Date:  2022-05-02       Impact factor: 38.272

7.  Mesenchymal Stem Cell Therapy Protects Lungs from Radiation-Induced Endothelial Cell Loss by Restoring Superoxide Dismutase 1 Expression.

Authors:  Diana Klein; Jennifer Steens; Alina Wiesemann; Florian Schulz; Farnusch Kaschani; Katharina Röck; Masahiro Yamaguchi; Florian Wirsdörfer; Markus Kaiser; Jens W Fischer; Martin Stuschke; Verena Jendrossek
Journal:  Antioxid Redox Signal       Date:  2016-11-14       Impact factor: 8.401

Review 8.  The adenosine pathway in immuno-oncology.

Authors:  Bertrand Allard; David Allard; Laurence Buisseret; John Stagg
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

Review 9.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

10.  Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Authors:  Violetta Ritter; Franziska Krautter; Diana Klein; Verena Jendrossek; Justine Rudner
Journal:  Cell Death Dis       Date:  2021-07-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.